Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer

Clinical Cancer Research

Volumn 14, Issue 19, 2008, Pages 6336-6342

  Lester, James E ^a,e   Dodwell, David ^c   Purohit, Omprakash P ^a   Gutcher, Sandra A ^a   Ellis, Susan P ^a   Thorpe, Ruth ^c   Horsman, Janet M ^a   Brown, Janet E ^d   Hannon, Rosemary A ^b   Coleman, Robert E ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; IBANDRONIC ACID; PLACEBO; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLUSHING; FRACTURE; HUMAN; INDIGESTION; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; NAUSEA; OSTEOPENIA; POSTMENOPAUSE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; BONE DISEASE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; LUMBAR VERTEBRA; MIDDLE AGED; PATHOLOGY;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; BREAST NEOPLASMS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; NITRILES; PLACEBOS; TRIAZOLES;

EID: 58149166777     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5101     Document Type: Article

References (24)

1. The ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
2. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-70.
3. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
4. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG1-98. J Clin Oncol 2007;25:486-92.
5. Dowsett M, Jones A, Johnston S, et al. In vivo measurement of aromatase inhibition by Letrozole in postmenopausal patients with breast cancer. Clin Cancer Res 1995;1:1511-5.
6. Geisler J, King N, Dowsett L. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74:1286-91.
7. Geisler J, King N, Anker G. In vivo inhibition of aromatisation by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089-93.
8. Cummings SR, Browner W, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 1998;339:733-8.
9. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29.
10. Eastell R, Adams JE, Coleman R, et al. Effect of anastrozole on bone mineral density: 5-year results from the ATAC trial (18233230). J Clin Oncol 2008;26:1051-7.
11. Chesnut C, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Min Res 2004;19:1241-9.
12. Liberman U, Weiss S, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
13. Harris S, Watts N, Gennant H, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-52.
14. Black D, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
15. Reginster J, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the mobile study. Ann Rheum Dis 2006;65:654-61.
16. Brufsky A, Harker WG, Beck T, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829-36.
17. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian breast and colorectal cancer study group. J Clin Oncol 2007;25:820-8.
18. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
19. Eastell R, Hannon RA Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006;21:1215-23.
20. Eastell R, Van Poznack C, Hannon RA, et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis. J Bone Miner Res 2007;22:S113, abstract S300.
21. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American society for bone and mineral research. J Bone Miner Res 2007;22:1479-91.
22. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the intergroup exemestane study (IES): a randomised controlled study. Lancet Oncol 2007;8:119-27.
23. Hadji P, Body J-J, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008;19:1407-16.
24. Reid D, Doughty J, Eastell R. Guidance for the management of breast cancer treatment induced bone loss. A consensus position statement from a UK Expert Group. Cancer Treat Rev 2008;34 Suppl 1:S3-18.